Access the world's leading financial data and tools

Subscribe for $2
Overview
Profile

AC Immune stock

ACIU
CH0329023102
A2AR5F

Price

2.90
Today +/-
+0.06
Today %
+2.02 %

AC Immune stock price

%
Weekly
Details

Price

ⓘ

Overview

The Quote Chart provides detailed and dynamic insights into the AC Immune stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.

Intraday Feature

The intraday feature provides real-time data, allowing investors to view the AC Immune stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.

Total Return and Relative Price Change

View the total return of the AC Immune stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.

Interpretation and Investment

Utilize the comprehensive data presented in the Quote Chart to analyze AC Immune's market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.

AC Immune Stock Price History

DateAC Immune Price
12/3/20242.90 undefined
12/2/20242.85 undefined
11/29/20243.00 undefined
11/27/20242.96 undefined
11/26/20243.01 undefined
11/25/20243.03 undefined
11/22/20243.02 undefined
11/21/20242.92 undefined
11/20/20242.86 undefined
11/19/20242.89 undefined
11/18/20242.77 undefined
11/15/20242.83 undefined
11/14/20243.16 undefined
11/13/20242.82 undefined
11/12/20242.70 undefined
11/11/20242.79 undefined
11/8/20242.80 undefined
11/7/20242.85 undefined
11/6/20242.71 undefined
11/5/20242.80 undefined
11/4/20242.54 undefined

AC Immune Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into AC Immune, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by AC Immune from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects AC Immune’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of AC Immune. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into AC Immune’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing AC Immune’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on AC Immune’s growth potential.

AC Immune Revenue, EBIT and net profit per share

DateAC Immune RevenueAC Immune EBITAC Immune Net Income
2030e417.11 M undefined270.86 M undefined234.59 M undefined
2029e353.29 M undefined221.62 M undefined165.15 M undefined
2028e110.41 M undefined-2.01 M undefined24.33 M undefined
2027e81.43 M undefined-22.93 M undefined6.98 M undefined
2026e103 M undefined-16.4 M undefined-24.65 M undefined
2025e49.56 M undefined-43.94 M undefined-39.23 M undefined
2024e27.43 M undefined-53.15 M undefined-53.58 M undefined
202314.8 M undefined-53.62 M undefined-54.23 M undefined
20223.9 M undefined-70.8 M undefined-70.8 M undefined
20210 undefined-79 M undefined-73 M undefined
202015.4 M undefined-61.3 M undefined-61.9 M undefined
2019110.5 M undefined44.5 M undefined45.4 M undefined
20187.2 M undefined-49.6 M undefined-51 M undefined
201720.3 M undefined-22.5 M undefined-26.4 M undefined
201623.2 M undefined-10.5 M undefined-7.1 M undefined
201539.1 M undefined18.6 M undefined20.3 M undefined
201430.3 M undefined10.7 M undefined10.7 M undefined
20138.6 M undefined-11.5 M undefined-11.2 M undefined

AC Immune Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (M)REVENUE GROWTH (%)GROSS MARGIN (%)GROSS INCOME (M)NET INCOME (M)NET INCOME GROWTH (%)SHARES (M)DOCUMENTS
201320142015201620172018201920202021202220232024e2025e2026e2027e2028e2029e2030e
8303923207110150314274910381110353417
-275.0030.00-41.03-13.04-65.001,471.43-86.36--366.6792.8681.48110.20-21.3635.80220.9118.13
------------------
000000000000000000
-111020-7-26-5145-61-73-70-54-53-39-24624165234
--190.91100.00-135.00271.4396.15-188.24-235.5619.67-4.11-22.86-1.85-26.42-38.46-125.00300.00587.5041.82
53.953.953.950.157.161.871.171.97583.684.690000000
------------------
Details

Keystats

ⓘ

Revenue and Growth

The AC Immune Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the AC Immune is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETSCASH BALANCE (M)RECEIVABLES (M)OTHER REC. (M)INVENTORIES (M)OTHER CURRENT LIAB. (M)CURRENT ASSETS (M)TANGIBLE ASSETS (M)LONG-T. INVEST. (k)LONG-T. REC. (M)INTANGIBLE ASSETS (M)GOODWILL (M)OTHER NON-CURRENT ASSETS (k)NON-CURRENT ASSETS (M)TOTAL ASSETS (M)LIABILITIESCOMMON STOCK (M)ADDITIONAL PAID-IN CAPITAL (M)RETAINED EARNINGS (M)OTHER EQUITY (M)UNREAL. GAINS/LOSSES (M)EQUITY (M)LIABILITIES (M)PROVISIONS (M)OTHER SHORT-TERM LIAB. (M)SHORT-TERM DEBTS (M)LONG-TERM DEBT PORTION (M)SHORT-TERM REC. (M)LONG-T. LIAB. (M)DEFERRED TAXES (M)OTHER LIAB. (M)LONG-T. LIABILITIES (M)DEBT (M)TOTAL CAPITAL (M)
20132014201520162017201820192020202120222023
                     
11.33.376.5152.2124.4186.5288.6225.9198.2122.6103.05
00.100.92.83.71.11.610.415.05
0.225.90.30.50.90.40.30.30.40.40.62
00000000000
0.50.42.51.31.42.42.8434.76.44
1229.779.3154.9129.5193292.8231.8202.6128.1125.15
0.70.50.51.12.43.36.26.687.16.88
000000300300400400361
00000000000
0000000050.450.450.42
00000000000
10010010010010030000000
0.80.60.61.22.53.66.56.958.857.957.66
12.830.379.9156.1132196.6299.3238.7261.4186182.81
                     
0.80.90.91.11.11.41.41.51.81.82.09
73.283.1110.5188.2188.3298.1346.5346.9431.3431.3474.91
-70.1-60.5-40.4-46.9-72.6-121.9-75.5-132.9-200.9-264-316.2
0000000000-0.05
00000000000
3.923.571142.4116.8177.6272.4215.5232.2169.1160.75
1.21.61.741.120.12.220.91.68
2.72.64.35.48.310.411.811.116.79.411.09
3.90.200.50.40.44.50.30.70.60.14
00000000000
000000.31.10.40.60.50.67
7.84.469.99.813.117.5142011.413.58
00000.40.21.81.82.32.32.83
00000000000
0.92.42.83.855.77.57.57.13.25.77
0.92.42.83.85.45.99.39.39.45.58.59
8.76.88.813.715.21926.823.329.416.922.17
12.630.379.8156.1132196.6299.2238.8261.6186182.92
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of AC Immune provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand AC Immune's financial health and stability.

Assets

AC Immune's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that AC Immune must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of AC Immune after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into AC Immune's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (M)DEPRECIATION (M)DEFERRED TAXES (M)CHANGES IN WORKING CAPITAL (M)NON-CASH ITEM (M)PAID INTEREST (M)PAID TAXES (M)NET CASH FLOW FROM OPERATING ACTIVITIES (M)CAPITAL EXPENDITURES (M)CASH FLOW FROM INVESTING ACTIVITIES (M)CASH FLOW FROM OTHER INVESTING ACTIVITIES (M)INTEREST INCOME AND EXPENSES (M)NET DEBT CHANGE (M)NET CHANGE IN EQUITY (M)CASH FLOW FROM FINANCING ACTIVITIES (M)CASH FLOW FROM OTHER FINANCING ACTIVITIES ()TOTAL DIVIDENDS PAID (M)NET CHANGE IN CASH FLOW (M)FREE CASH FLOW (M)SHARE-BASED COMPENSATION (M)
20132014201520162017201820192020202120222023
-111020-7-26-5045-61-73-70-54
00000011222
00000000000
-8-29242-215-46-8-14
000076592710
00000000000
00000000000
-19-1744-5-22-4455-59-65-73-60
0000-1-1-1-1-2-10
0000-1-32-6628-532365
00000-30-6530-512566
00000000000
0000005002200
1010298201110017043
1092778010949040-143
---1.00-4.00--2.00-----
00000000000
-9-77375-273237-32-78-5046
-20.05-17.7543.84-6.55-23.89-45.9453.33-61.23-68.33-74.81-61.21
00000000000

AC Immune stock margins

The AC Immune margin analysis displays the gross margin, EBIT margin, as well as the profit margin of AC Immune. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for AC Immune.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the AC Immune's sales revenue. A higher gross margin percentage indicates that the AC Immune retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the AC Immune's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the AC Immune's total revenue generated. When comparing the revenue margin year over year, investors can gauge the AC Immune's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the AC Immune. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the AC Immune's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

AC Immune Margin History

AC Immune Gross marginAC Immune Profit marginAC Immune EBIT marginAC Immune Profit margin
2030e0 %64.94 %56.24 %
2029e0 %62.73 %46.75 %
2028e0 %-1.82 %22.04 %
2027e0 %-28.16 %8.58 %
2026e0 %-15.92 %-23.93 %
2025e0 %-88.66 %-79.15 %
2024e0 %-193.74 %-195.31 %
20230 %-362.3 %-366.41 %
20220 %-1,815.38 %-1,815.38 %
20210 %0 %0 %
20200 %-398.05 %-401.95 %
20190 %40.27 %41.09 %
20180 %-688.89 %-708.33 %
20170 %-110.84 %-130.05 %
20160 %-45.26 %-30.6 %
20150 %47.57 %51.92 %
20140 %35.31 %35.31 %
20130 %-133.72 %-130.23 %

AC Immune Stock Sales Revenue, EBIT, Earnings per Share

The AC Immune earnings per share therefore indicates how much revenue AC Immune has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue AC Immune earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates AC Immune's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of AC Immune’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating AC Immune's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

AC Immune Revenue, EBIT and net profit per share

DateAC Immune Sales per ShareAC Immune EBIT per shareAC Immune Earnings per Share
2030e4.22 undefined0 undefined2.37 undefined
2029e3.57 undefined0 undefined1.67 undefined
2028e1.12 undefined0 undefined0.25 undefined
2027e0.82 undefined0 undefined0.07 undefined
2026e1.04 undefined0 undefined-0.25 undefined
2025e0.5 undefined0 undefined-0.4 undefined
2024e0.28 undefined0 undefined-0.54 undefined
20230.17 undefined-0.63 undefined-0.64 undefined
20220.05 undefined-0.85 undefined-0.85 undefined
20210 undefined-1.05 undefined-0.97 undefined
20200.21 undefined-0.85 undefined-0.86 undefined
20191.55 undefined0.63 undefined0.64 undefined
20180.12 undefined-0.8 undefined-0.83 undefined
20170.36 undefined-0.39 undefined-0.46 undefined
20160.46 undefined-0.21 undefined-0.14 undefined
20150.73 undefined0.35 undefined0.38 undefined
20140.56 undefined0.2 undefined0.2 undefined
20130.16 undefined-0.21 undefined-0.21 undefined

AC Immune business model

AC Immune SA is a biopharmaceutical company specializing in the discovery and development of drugs for the treatment of neurodegenerative diseases as well as cancer. It was founded in 2003 by a group of leading researchers in the field of neurodegeneration and is based in Lausanne, Switzerland. The company has established itself as one of the leading companies in Alzheimer's research in recent years. AC Immune SA focuses on developing drugs targeting protein aggregation that occurs in Alzheimer's and other neurodegenerative diseases in the brain. It has developed an innovative platform technology that allows for the development of specific antibodies that selectively bind to certain toxic or disease-causing proteins. AC Immune has developed a variety of proprietary technologies and platforms that enable rapid and efficient identification, testing, and optimization of therapeutics. Its main products are antibodies that therapeutically target Alzheimer's, Parkinson's, TAU, and Alpha-Synuclein prions. These antibodies that target protein disease-related plaques help slow disease progression and alleviate symptoms. AC Immune has also developed and tested drugs for cancer treatment. The company operates in two main segments: research and development, as well as clinical studies. It has a strong pipeline of products in development that are in various stages of clinical trials. These products target various diseases including Alzheimer's, Parkinson's, advanced stage cancer, prion diseases, neurodegenerative sanatoria, and Down syndrome. AC Immune SA collaborates closely with various academic research institutions, biotechnology companies, pharmaceutical companies, and government agencies to bring innovative therapies to market. It has formed numerous partnerships and alliances with renowned partners in the pharmaceutical, biotech, and life science industries to accelerate the translation of promising therapeutic approaches into clinical applications. Recently, AC Immune SA announced a partnership with Genentech, a leading company in the development of biological therapies and diagnostic procedures. The two companies are working together to develop treatments for Alzheimer's and several other neurodegenerative diseases. Another example is the collaboration with Eli Lilly and Company for the use of ACI-3024 in the fight against tauopathies, including Alzheimer's disease and progressive supranuclear palsy. AC Immune SA has a strong foundation in scientific research and development, as well as in the commercialization of therapeutics. The company has a comprehensive product pipeline aimed at developing innovative therapy options for patients with neurodegenerative diseases and cancer. With its proprietary technology platform and partnerships with leading companies in the biotech and pharmaceutical industries, AC Immune SA has great potential to make significant advances in the development of therapies that improve patients' lives and enhance their quality of life. AC Immune is one of the most popular companies on Eulerpool.com.

AC Immune SWOT Analysis

Strengths

1. Strong Research and Development Capabilities: AC Immune SA possesses advanced expertise in neurodegenerative diseases, specifically in the field of Alzheimer's disease.

2. Robust Pipeline: The company has a diversified pipeline of potential therapeutics and diagnostics targeting amyloid and tau proteins, which are known to be key drivers of Alzheimer's.

3. Strategic Partnerships: AC Immune SA has established collaborations with leading pharmaceutical companies, enabling them to leverage their research capabilities and access additional resources.

Weaknesses

1. Dependency on Partnerships: The reliance on partnerships for funding and development support puts AC Immune SA at risk of potential delays or setbacks if collaborations do not meet expectations.

2. Limited Product Portfolio: As a biopharmaceutical company focused on neurodegenerative diseases, AC Immune SA's product portfolio is currently concentrated in a specific therapeutic area, limiting diversification.

3. Regulatory Challenges: Developing treatments for Alzheimer's disease poses significant regulatory hurdles and uncertainties, which may impact the approval process and timelines.

Opportunities

1. Growing Aging Population: The increasing global prevalence of Alzheimer's disease offers significant market potential for AC Immune SA's innovative therapies and diagnostics.

2. Emerging Diagnostic Technologies: Advances in diagnostic technologies may present opportunities for AC Immune SA to develop improved diagnostic tools for early detection and monitoring of Alzheimer's.

3. Potential for Combination Therapies: Collaboration with other pharmaceutical companies to develop combination therapies may enhance treatment efficacy and open new market opportunities.

Threats

1. Intense Competition: AC Immune SA faces competition from large pharmaceutical companies, biotechnology firms, and academic institutions also working on Alzheimer's disease treatments.

2. Economic and Financial Uncertainties: Market volatility, economic downturns, or lack of funding could impact AC Immune SA's ability to secure necessary investments for research and development.

3. Stringent Regulatory Environment: The stringent regulatory requirements for drug approval may result in extended timelines, increased costs, and potential failure to gain regulatory clearance.

LIMITED TIME OFFER

The World’s Best Investors Are On Eulerpool

Subscribe for $2

AC Immune Eulerpool Fair Value

Details

Fair Value

ⓘ

Understanding Fair Value

The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.

Income-Based Fair Value

This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.

Example 2022

Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)

Revenue-Based Fair Value

It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.

Example 2022

Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)

Dividend-Based Fair Value

This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.

Example 2022

Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)

Expectations and Forecasts

Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.

Comparative Analysis

Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.

AC Immune historical P/E ratio, EBIT multiple, and P/S ratio

LIMITED TIME OFFER

The World’s Best Investors Are On Eulerpool

Subscribe for $2

AC Immune shares outstanding

The number of shares was AC Immune in 2023 — This indicates how many shares 84.695 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue AC Immune earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates AC Immune's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of AC Immune’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating AC Immune's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

LIMITED TIME OFFER

The World’s Best Investors Are On Eulerpool

Subscribe for $2
Unfortunately, there are currently no price targets and forecasts available for AC Immune.

AC Immune latest earnings and earnings surprises

DateEPS EstimateEPS ActualQuarterly report
9/30/2024-0.2 0.05  (125.04 %)2024 Q3
6/30/20240.27 -0.23  (-183.76 %)2024 Q2
3/31/2024-0.14 -0.18  (-30.62 %)2024 Q1
12/31/2023-0.12 -0.05  (56.75 %)2023 Q4
9/30/20230.03 -0.18  (-787.02 %)2023 Q3
6/30/2023-0.2 -0.2  (0.65 %)2023 Q2
3/31/2023-0.23 -0.21  (10.29 %)2023 Q1
12/31/2022-0.26 -0.23  (10.54 %)2022 Q4
9/30/2022-0.25 -0.16  (35.12 %)2022 Q3
6/30/2022-0.24 -0.23  (2.95 %)2022 Q2
1
2
3
4

Eulerpool ESG Scorecard© for the AC Immune stock

Eulerpool World ESG Rating (EESG©)

64/ 100

🌱 Environment

36

👫 Social

87

🏛️ Governance

70

Environment

Scope 1 - Direct Emissions
Scope 2 - Indirect emissions from purchased energy
Scope 3 - Indirect emissions within the value chain
Total CO₂ emissions
CO₂ reduction strategy
Coal energy
Nuclear power
Animal experiments
Fur & Leather
Pesticides
Palm Oil
Tobacco
Genetically modified organisms
Climate concept
Sustainable forestry
Recycling regulations
Environmentally friendly packaging
Hazardous substances
Fuel consumption and efficiency
Water consumption and efficiency

Social

Percentage of female employees57
Percentage of women in management
Percentage of Asian employees
Share of Asian management
Percentage of Hispanic/Latino employees
Hispano/Latino Management share
Percentage of Black employees
Black Management Share
Percentage of white employees
White Management Share
Adult content
Alcohol
Weapons
Firearms
Gambling
Military contracts
Human rights concept
Privacy concept
Occupational health and safety
Catholic

Governance (Corporate Governance)

Environmental reporting
Stakeholder Engagement
Call Back Policies
Antitrust law

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

AC Immune shareholders

%
Name
Stocks
Change
Date
19.03673 % BVF Partners L.P.18,834,9364,263,7006/30/2024
12.12856 % Varuma AG11,999,999012/31/2023
6.64857 % Affiris AG6,578,100-3,555,37412/15/2023
2.44717 % Pfeifer (Andrea M. A Ph.D.)2,421,22656,30812/31/2023
1.93441 % BlackRock Financial Management, Inc.1,913,91006/30/2024
1.82707 % Redmile Group, LLC1,807,704-199,3276/30/2024
1.13404 % Wells Fargo Advisors1,122,0172,3146/30/2024
0.96227 % Platinum Asset Management952,069-142,9576/30/2024
0.83384 % Avidity Partners Management LP825,000-3,645,0006/30/2024
0.65907 % Renaissance Technologies LLC652,079136,3006/30/2024
1
2
3
4
5
...
10

AC Immune Executives and Management Board

Prof. Dr. Andrea Pfeifer

(66)
AC Immune Chief Executive Officer, Co-Founder, Director (since 2003)
Compensation 993,000

Prof. Dr. Monika Buetler

(63)
AC Immune Non-Executive Independent Director
Compensation 208,000

Dr. Douglas Williams

(65)
AC Immune Independent Chairman of the Board
Compensation 194,000

Dr. Monica Shaw

(46)
AC Immune Non-Executive Independent Director
Compensation 194,000

Mr. Thomas Graney

(58)
AC Immune Non-Executive Independent Director
Compensation 142,000
1
2
3

Most common questions regarding AC Immune

What values and corporate philosophy does AC Immune represent?

AC Immune SA represents a set of core values and a corporate philosophy that guide its actions and decision-making. The company is committed to advancing precision medicine to combat neurodegenerative diseases. AC Immune SA focuses on the discovery, development, and commercialization of innovative therapies targeting misfolded proteins, with a particular emphasis on Alzheimer's disease. By leveraging its deep scientific expertise and collaborative approach, AC Immune SA strives to make a meaningful impact on patients' lives. The company's dedication to scientific excellence, integrity, innovation, and patient-centeredness drives its pursuit of groundbreaking treatments and solutions for neurodegenerative disorders.

In which countries and regions is AC Immune primarily present?

AC Immune SA is primarily present in multiple countries and regions across the globe. Some of the key areas where the company has a significant presence include Switzerland, where AC Immune SA is based, as well as the United States, where it operates through its subsidiaries. Additionally, AC Immune SA has a growing presence in various European countries, including France, Germany, and the United Kingdom. With its global reach, AC Immune SA is continuously expanding its footprint and partnerships to advance its mission in pioneering precision medicine for neurodegenerative diseases.

What significant milestones has the company AC Immune achieved?

AC Immune SA, a renowned biotech company, has achieved several significant milestones. It has successfully advanced its proprietary clinical-stage pipeline, focusing on neurodegenerative diseases like Alzheimer's and Parkinson's. AC Immune has also established strategic collaborations with renowned pharmaceutical companies, reinforcing its position in the industry. The company has achieved positive clinical trial results for its innovative therapeutic candidates, demonstrating promising efficacy and safety profiles. AC Immune's dedication to pioneering precision medicine approaches and its strong focus on research and development have been instrumental in its continuous growth and recognition in the field of neurodegenerative diseases.

What is the history and background of the company AC Immune?

AC Immune SA is a leading biopharmaceutical company with a rich history and background. Founded in 2003, AC Immune has been steadfastly committed to discovering, developing, and delivering innovative therapies for neurodegenerative diseases like Alzheimer's and Parkinson's disease. With a strong focus on precision medicine, AC Immune strives to address unmet medical needs by targeting pathological proteins such as tau and alpha-synuclein. Leveraging its state-of-the-art proprietary platforms and strategic collaborations, the company has made significant progress in advancing its robust pipeline of therapeutics and diagnostics. AC Immune's unwavering dedication to improving patients' lives continues to drive its pioneering research and development efforts in the field of neurodegenerative diseases.

Who are the main competitors of AC Immune in the market?

The main competitors of AC Immune SA in the market are companies such as Biogen Inc., Roche Holding AG, and Eli Lilly and Company.

In which industries is AC Immune primarily active?

AC Immune SA is primarily active in the pharmaceutical and biotechnology industries.

What is the business model of AC Immune?

The business model of AC Immune SA focuses on developing innovative therapeutics and diagnostics to prevent and treat neurodegenerative diseases, such as Alzheimer's disease. AC Immune SA employs a unique approach combining precision medicine and immunotherapy to target misfolded proteins, like tau and amyloid-beta, which play a crucial role in the progression of these diseases. By leveraging its proprietary platforms and strategic partnerships, AC Immune SA aims to bring potential disease-modifying treatments and accurate diagnostic tools to market, addressing the unmet needs in neurodegenerative disorders.

What is the P/E ratio of AC Immune 2024?

The AC Immune P/E ratio is -4.59.

What is the P/S ratio of AC Immune 2024?

The AC Immune P/S ratio is 8.97.

What is the Quality Investing of AC Immune?

The Quality Investing for AC Immune is 4/10.

What is the revenue of AC Immune 2024?

The expected AC Immune revenue is 27.43 M CHF.

How high is the profit of AC Immune 2024?

The expected AC Immune profit is -53.58 M CHF.

What is the business model of AC Immune

AC Immune SA is a biotechnology company that focuses on the development of innovative therapies for the treatment of neurodegenerative diseases such as Alzheimer's, Parkinson's, and Amyotrophic Lateral Sclerosis (ALS). The company covers several areas, including research and development, clinical development, production, and distribution of medications. Currently, AC Immune SA is working on several product candidates in different phases of clinical development. This includes a range of monoclonal antibodies and small molecules that target specific neurodegenerative receptors and proteins such as beta-amyloid and tau protein. AC Immune SA's product candidates aim to eliminate disease-causing proteins by supporting the immune defense of the body or directly inhibiting protein formation. A major product of AC Immune SA is the monoclonal antibody ACI-24, which targets beta-amyloid, a buildup of proteins that plays an important role in Alzheimer's disease. ACI-24 is currently in phase II of clinical development. Another product candidate of AC Immune SA is the monoclonal antibody ACI-35, which targets tau protein, which promotes the formation of β-amyloid. ACI-35 is in preclinical development. Furthermore, AC Immune SA utilizes its proprietary platform technology to advance the development of biomarkers that can be used in the diagnosis of neurodegenerative diseases. AC Immune SA has a number of partnerships with pharmaceutical companies such as Roche, Genentech, and Johnson & Johnson to market and further develop its products and technologies. AC Immune SA pursues a business model that aims to manufacture patented therapeutic agents tailored to the needs of patients with neurodegenerative diseases. This business model also includes close collaboration with other pharmaceutical companies and academic institutions to unlock additional clinical benefits and accelerate commercialization. Through its product pipeline and platform technology, as well as strategic partnerships, AC Immune SA offers its customers and patients a comprehensive portfolio of therapeutic products and services aimed at revolutionizing the treatment of neurodegenerative diseases. Overall, AC Immune SA has earned an excellent reputation through its continuous search for innovative solutions and its commitment to collaboration in a highly competitive market.

What is the AC Immune dividend?

AC Immune pays a dividend of 0 CHF distributed over payouts per year.

How often does AC Immune pay dividends?

The dividend cannot currently be calculated for AC Immune or the company does not pay out a dividend.

What is the AC Immune ISIN?

The ISIN of AC Immune is CH0329023102.

What is the AC Immune WKN?

The WKN of AC Immune is A2AR5F.

What is the AC Immune ticker?

The ticker of AC Immune is ACIU.

How much dividend does AC Immune pay?

Over the past 12 months, AC Immune paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, AC Immune is expected to pay a dividend of 0 CHF.

What is the dividend yield of AC Immune?

The current dividend yield of AC Immune is .

When does AC Immune pay dividends?

AC Immune pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of AC Immune?

AC Immune paid dividends every year for the past 0 years.

What is the dividend of AC Immune?

For the upcoming 12 months, dividends amounting to 0 CHF are expected. This corresponds to a dividend yield of 0 %.

In which sector is AC Immune located?

AC Immune is assigned to the 'Health' sector.

Wann musste ich die Aktien von AC Immune kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of AC Immune from 12/3/2024 amounting to 0 CHF, you needed to have the stock in your portfolio before the ex-date on 12/3/2024.

When did AC Immune pay the last dividend?

The last dividend was paid out on 12/3/2024.

What was the dividend of AC Immune in the year 2023?

In the year 2023, AC Immune distributed 0 CHF as dividends.

In which currency does AC Immune pay out the dividend?

The dividends of AC Immune are distributed in CHF.

All fundamentals about AC Immune

Our stock analysis for AC Immune Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of AC Immune Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.